Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- TheraCryf received a Korean patent grant for its Orexin-1R antagonist in addiction, completing broad intellectual property coverage across major commercial markets including the US and EU. - The company achieved its first manufacturing milestone ahead of schedule, successfully scaling up production from gram quantities to 0.5kg and initiating 2kg human-grade material manufacturing. - An optimal formulation using Amorphous Solid Dispersions has been identified, enabling a straightforward drug-in-capsule approach for first-in-human studies with enhanced oral absorption. - The company confirmed selection of a non-rodent species for 28-day toxicity studies scheduled to commence in early 2026, supporting clinical trial applications.
- CN Bio has formed a strategic partnership with Pharmaron to validate and integrate its PhysioMimix organ-on-a-chip technology across drug discovery applications, reducing reliance on animal testing. - The collaboration will initially focus on disease modeling, toxicity testing, and ADME studies, with plans to expand into novel applications addressing unmet needs in pharmaceutical R&D. - This partnership aligns with recent FDA announcements to phase out animal testing requirements for monoclonal antibodies, as the global organ-on-a-chip market is projected to reach $388 million by 2028.
- Complement Therapeutics has raised €72 million ($79M) in Series A funding to advance CTx001, a single-injection gene therapy targeting geographic atrophy, into Phase 1b clinical trials. - The University of Manchester spinout is developing an AAV-based therapy to address geographic atrophy, an advanced form of AMD affecting 8 million people globally with limited treatment options. - The company has initiated a natural history study (i-GAIN) and partnered with Pharmaron for AAV manufacturing, targeting first-in-human trials in late 2024.
